EXCIVA GmbH

• 20/01/2026
• Series B
• $59,817,135

EXCIVA GmbH

TARGETED DRUG RESCUE (TDR)
There are about 3,000 drugs that have been approved by at least one country in this world. Just a handful of drugs received approval prior to the creation of the modern FDA in 1938, including Merck's morphine in 1827 and aspirin in 1899. FDA approved 1,453 drugs as of 31 December 2013. Some of them are off the patent protection, i.e., they are generic drugs that are on the market for quite some time and are safe with known safety profiles. In addition, there are thousands of compounds that failed in clinical trials for lack of efficacy or some other reason and are abandoned. Rescuing and reusing these approved drugs and other candidates by repurposing for new indications and new uses is Targeted Drug Rescue (TDR).

Our TARGETD DRUG RESCUE program involves developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations, and methods of making and using such compositions, treatments, therapies, cures, prophylactics, supplements, formulations and kits thereof, and methods of treatments, therapies, cures, prophylactics, or supplements for a subject in need thereof burdened by ailments, conditions, diseases, or disorders comprising treatments, therapies, cures, prophylactics, supplements, or formulations comprising an effective amount of a substance such as a biologic, chemical, nutritional, and/or pharmaceutical, and compositions, wherein the substance can be a racemate, enantiomer, metabolite, derivative, or prodrug thereof, or a combination thereof:
https://trademarks.justia.com/876/95/exciva-87695736.html;
https://www.trademarkbank.com/trademarks/87195766;
https://trademarks.justia.com/871/95/exciva-87195766.html;

---

---